Tag: Immunotherapy
Infection Risk Up in Month After CAR T-Cell Immunotherapy
Infection rates increase in patients with ALL aged ≤26 years in first month, then decrease at days 29 to 90
SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression-free survival
FDA Labeling Restriction Quickly Reflected in Oncology Practice
FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
But not for corticosteroid-free clinical remission; also, ustekinumab superior to placebo
Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC
Initial breath analysis predicts individual treatment response to anti-PD-1 therapy at three months
Allergy Immunotherapy May Decrease Asthma Progression
Findings strongest for youngest patients with incident asthma treated in routine care
Underused Drug Combo May Up Survival in Lung Transplant
No antibody induction therapy with sirolimus plus tacrolimus associated with maximal survival
SAVED Score Can Predict Risk for VTE in Multiple Myeloma
Score outperforms current NCCN guidelines for MM patients receiving immunomodulatory therapy
Chemoimmunotherapy Regimen Approved to Treat DLBCL
Polivy approved in combination with bendamustine, rituximab for diffuse large B-cell lymphoma
Peanut Oral Immunotherapy May Up Allergic Reaction Risk
Increase seen in anaphylaxis risk, anaphylaxis frequency, epinephrine use with oral immunotherapy
